Hanmi Pharmaceutical to Present Its New Targeted Lung Cancer Drug ‘HM61713′ at 2015 ASCO Annual Meeting

SEOUL, South Korea

Image may be NSFW.
Clik here to view.

Hanmi Pharmaceutical co., Ltd. (KSE:128940) will present the results of the phase I/II domestic clinical trial of HM61713 in patients with EGFR mutation positive non-small cell lung cancer at the 51^st American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2015, in Chicago, USA.

During the conference, Hanmi Pharmaceutical will participate in a session on Lung Cancer-Non-Small Cell Metastatic, and will give a poster presentation on the results of the phase I/II domestic clinical trial with 195 patients of EGFR mutation positive non-small cell lung cancer administered with HM61713.

HM61713 selectively inhibits the mutation of signal delivery substance EGFR involved in the growth of cancer cells, and is evaluated as the third-generation EGFR tyrosine kinase inhibitor (TKI) which overcomes resistance and side effects after administration with previous EGFR TKIs Iressa^® and Tarceva^®.

Presentation Schedule (local time)

HM61713 (HM-EMSI-101)
Updated safety and efficacy results from I/II study of HM61713 in patients with EGFR mutation positive non-small cell lung cancer who failed previous EGFR-tyrosine kinase inhibitor, Poster Session, at 08:00 on Jun 1 (Mon).

Hanmi Pharmaceutical co., Ltd.
Hanmi Pharmaceutical is a Korea-based pharmaceutical company. The Company invests over 20 percent of its sales in R&D and has over 20 programs consisting of the novel long acting biologics including weekly Insulin, weekly to monthly GLP-1, and their combination for diabetes and obesity (collectively referred as Quantum Project), the novel targeted anti-cancer drugs with improved tolerance and safety profile and fixed-dose combination drugs. For more detail about the company, visit http://www.hanmipharm.com .

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150528005595/en/